Testing for Discordance at Metastatic Relapse: Does It Matter?

Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series

(2017) R. MacFarlane et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

(2011) Naoki Niikura et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer

(2011) Eitan Amir et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

(2009) C. Liedtke et al.   ANNALS OF ONCOLOGY

Inferring tumor progression from genomic heterogeneity

(2009) N. Navin et al.   GENOME RESEARCH

Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review

(2009) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

(2009) Sohrab P. Shah et al.   NATURE